✦ LIBER ✦

Impact of perceived stigma on inflammatory bowel disease patient outcomes

✍ Scribed by Tiffany H. Taft; Laurie Keefer; Christoph Leonhard; Michele Nealon-Woods

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 104 KB
Volume: 15
Category: Article
ISSN: 1078-0998
DOI: 10.1002/ibd.20864

No coin nor oath required. For personal study only.

✦ Synopsis

Background: Perceived stigma has been linked to disease outcome in several chronic illnesses. Stigmatization of illness often leads to increased psychological distress and poorer quality of life. While body stigma has been identified as a specific inflammatory bowel disease (IBD) patient concern, no study to date has systematically investigated the presence of stigma in IBD or its effects on disease course and management.

Methods: Participants were recruited online and through the Illinois chapter of the Crohn's & Colitis Foundation of America.

📜 SIMILAR VOLUMES

Does primary sclerosing cholangitis impa

Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease?

✍ Ashwin N. Ananthakrishnan; Dawn B. Beaulieu; Alex Ulitsky; Yelena Zadvornova; Su 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

Therapeutic impact of toll-like receptor

Therapeutic impact of toll-like receptors on inflammatory bowel diseases: A multiple-edged sword

✍ Elke Cario 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB

Recent studies have begun to define the mechanisms through which Toll-like receptors (TLRs) regulate intestinal homeostasis in health and disease. Current therapies for inflammatory bowel diseases (IBDs) mostly aim at interrupting the inflammatory cascade through agents that regulate TH1 or TH2 cyto

Impact of demographic factors, medicatio

Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease

✍ Johanna Haapamäki; Ulla Turunen; Risto P. Roine; Martti A. Färkkilä; Perttu E. T 📂 Article 📅 2009 🏛 Springer Netherlands 🌐 English ⚖ 178 KB

Clinical features and outcome of patient

Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: A case–control study

✍ Karen A. Hanson; Edward V. Loftus Jr; W. Scott Harmsen; Nancy N. Diehl; Alan R. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## Background: The role of narcotic use in patients with inflammatory bowel disease (IBD) is poorly defined. We sought to determine the clinical features of patients with IBD who use narcotics and factors associated with the discontinuation of narcotics. ## Methods: A centralized index was used

Frequency, phenotype, outcome, and thera

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients

✍ Daniel C. Baumgart; Ulrike Grittner; Andrea Steingräber; Marina Azzaro; Sandra P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

## Background: The monoclonal anti tumor necrosis factor (TNF) antibody adalimumab has recently been approved for Crohn's disease (CD) and evaluated for ulcerative colitis (UC). Cutaneous lesions associated with its administration have not been prospectively studied in inflammatory bowel disease (

Disability in inflammatory bowel disease

Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health

✍ Laurent Peyrin-Biroulet; Alarcos Cieza; William J. Sandborn; Nenad Kostanjsek; M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

The inflammatory bowel diseases (IBDs) are associated with a reduced quality of life. The impact of IBD on disability remains largely unknown. With the International Classification of Functioning, Disability, and Health (ICF) of the World Health Organization (WHO), we can now rely on a globally agre